PuriCore (LSE:PURI), the life sciences company focused on the control of infectious pathogens, announced that the US Patent and Trademark Office has granted US Patent No. 7,276,255, entitled Wound and Ulcer Treatment with Super-Oxidized Water relating to wound therapy methods. PuriCore’s methods employ hypochlorous acid at neutral or near-neutral pH to enhance the healing process for wounds. Related patents have been approved previously for PuriCore’s technology in the UK and Europe.
PuriCore’s invention is broadly drawn to methods of treating any open wound with hypochlorous acid solutions at neutral or near-neutral pH including two important processes, reducing wound bioburden and promoting tissue repair. Research data submitted with the patent shows that PuriCore’s invention method provides an optimum wound-healing environment by decreasing the bioburden of harmful microorganisms within the wound and by promoting skin cell proliferation and re-growth.
